Artelo Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a net loss of $1.768 million for the third quarter and a significant increase in cash and cash equivalents compared to year-end 2025.

Key Highlights

  • Net loss (Q3 2026): $1.768 million for the three months ended September 30, 2026, compared to $3.120 million in the same period of 2025, according to the filing.
  • Net loss (nine months): $7.153 million for the nine months ended September 30, 2026, versus $8.713 million for the same period in 2025.
  • Cash position: Cash and cash equivalents stood at $4.437 million as of September 30, 2026, up from $600 thousand at December 31, 2025.
  • Shares outstanding: 937,177 shares of common stock issued and outstanding as of November 11, 2026, compared to 74,779 shares at December 31, 2025.
  • Stockholders' equity: Total stockholders' equity was $6.236 million as of September 30, 2026, compared to a deficit of $1.272 million at December 31, 2025.
  • Total liabilities reduced: Total liabilities fell to $439 thousand at September 30, 2026, from $4.073 million at December 31, 2025, with convertible notes fully eliminated.
  • Loss per share (Q3 2026): Basic and diluted loss per common share of $3.19, compared to $88.80 in Q3 2025, based on weighted average shares of 554,197 and 35,136, respectively.

Artelo Biosciences Reports Q3 2026 Financial Results and Balance Sheet Changes

According to the filing, Artelo Biosciences (NASDAQ:ARTL) reported total operating expenses of $1.792 million for the three months ended September 30, 2026, consisting of $989 thousand in general and administrative expenses and $803 thousand in research and development expenses. This compares to total operating expenses of $3.089 million in the same quarter of 2025. For the nine-month period, total operating expenses were $6.986 million versus $8.618 million in the prior-year period.

The company's balance sheet showed notable changes from December 31, 2025 to September 30, 2026. The filing disclosed that cash and cash equivalents increased to $4.437 million from $600 thousand, while total assets grew to $6.675 million from $2.801 million. Total liabilities declined sharply to $439 thousand from $4.073 million, primarily reflecting the elimination of convertible notes and convertible notes held by related parties, which had totaled $609 thousand at year-end 2025. Accounts payable and accrued liabilities also fell from $3.035 million to $284 thousand.

The increase in stockholders' equity reflected several equity transactions during the nine-month period, as disclosed in the statements of stockholders' equity. These included common shares issued for cash, net of issuance costs, conversion of convertible notes to common stock, and warrant exercises. The accumulated deficit grew to $70.168 million at September 30, 2026, from $63.015 million at December 31, 2025. The registrant is classified as a non-accelerated filer and a smaller reporting company, and had 937,177 shares of common stock issued and outstanding as of November 11, 2026.

What Was Disclosed

Artelo Biosciences filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $1.768 million, a year-to-date net loss of $7.153 million, cash of $4.437 million, and a shift from a stockholders' deficit to positive equity of $6.236 million.